Sarepta Therapeutics (NASDAQ:SRPT) Given New $15.00 Price Target at Leerink Partners

Sarepta Therapeutics (NASDAQ:SRPT) had its target price boosted by Leerink Partners from $12.00 to $15.00 in a research report released on Tuesday morning,Benzinga reports. Leerink Partners currently has a market perform rating on the biotechnology company’s stock.

Several other equities research analysts have also recently commented on SRPT. Sanford C. Bernstein began coverage on shares of Sarepta Therapeutics in a research report on Tuesday, July 29th. They set a “market perform” rating and a $13.00 price target for the company. Scotiabank upgraded shares of Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price target for the company in a research report on Friday, June 6th. Bank of America lifted their price target on shares of Sarepta Therapeutics to $17.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 20th. William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 29th. Finally, Piper Sandler lifted their price target on shares of Sarepta Therapeutics to $15.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 29th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $42.36.

Sarepta Therapeutics Stock Up 0.2%

Shares of NASDAQ:SRPT opened at $17.64 on Tuesday. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $138.81. The company has a 50 day moving average of $17.79 and a 200-day moving average of $42.68. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -20.28 and a beta of 0.49.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company had revenue of $611.09 million during the quarter, compared to analysts’ expectations of $530.66 million. During the same quarter in the previous year, the company earned $0.07 EPS. Sarepta Therapeutics’s revenue was up 68.4% on a year-over-year basis. On average, sell-side analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Byrne Asset Management LLC bought a new position in Sarepta Therapeutics in the first quarter valued at approximately $30,000. Center for Financial Planning Inc. bought a new position in Sarepta Therapeutics in the first quarter valued at approximately $31,000. Logan Capital Management Inc. bought a new position in Sarepta Therapeutics in the fourth quarter valued at approximately $61,000. Ancora Advisors LLC lifted its stake in Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 300 shares in the last quarter. Finally, Pandora Wealth Inc. bought a new position in Sarepta Therapeutics in the first quarter valued at approximately $45,000. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.